What are the clinical presentation, diagnostic approach, and management recommendations for infection with human coronavirus OC43 (HCoV‑OC43)?

Human coronavirus OC43 (HCoV‑OC43): Presentation, diagnosis, and management

Bold recommendation: Treat HCoV‑OC43 like other non‑SARS/MERS/COVID seasonal coronaviruses: diagnose with multiplex NAAT from nasopharyngeal specimens, provide supportive care only (oxygen as needed), avoid empiric antivirals, and reserve ICU-level respiratory support for hypoxemia—because no guideline‑endorsed antiviral improves mortality, morbidity, or quality of life. 1, 2

Clinical presentation (what to look for)

• Typical: common‑cold symptoms (rhinorrhea, congestion, sore throat, cough ± fever). Exacerbations of asthma/COPD may occur, otitis media in children. Lower respiratory tract disease is uncommon but possible in infants, older adults, and the immunocompromised. 1
• Reported phenotypes:
  • Adults: influenza‑like illness most common; pneumonia and COPD exacerbations occur; hospitalizations >50% in some series but mortality low in immunocompetent adults. 3
  • Children: mostly URTI; LRTI risk rises with coinfections; ICU/death rare. 4
  • Severe disease clusters in high‑risk groups (diabetes, chronic lung/kidney disease, immunosuppressed); ICU admission and mechanical ventilation reported; bacterial coinfection worsens outcomes. 5
• Seasonality/epidemiology: winter predominance; highest detection in ages 0–4 years; suppressed circulation during COVID‑19 NPIs with partial rebound thereafter. 6

Diagnostic approach (stepwise, specific)

1. Who to test
   • Any viral respiratory syndrome where SARS‑CoV‑2/Influenza/RSV tests are negative or differential remains broad, particularly in winter or in high‑risk hosts. [General; aligned with 1]
2. What to order (preferred first)
   • Multiplex respiratory NAAT (PCR) on nasopharyngeal (or mid‑turbinate) swab—detects OC43 alongside other viruses and clarifies coinfections. 1, 7
3. When lower tract testing/imaging
   • If hypoxemia, pneumonia on exam, or clinical deterioration: obtain chest imaging and consider lower respiratory tract specimen NAAT if intubated. Follow labs (CBC, CRP) to assess severity; these monitoring principles mirror best supportive care for viral pneumonias. 2
4. What not to rely on
   • Serology is not used for acute OC43 diagnosis; culture/IF are research/specialty methods only. 1, 8
5. Key pitfalls to avoid
   • Do not assume COVID‑19 on CT alone; multiplex PCR distinguishes OC43 from SARS‑CoV‑2. 7
   • Do not attribute all severe disease to OC43 without checking for bacterial coinfection; coinfection increases morbidity. 5

Management (prioritize mortality, morbidity, QoL)

• Outpatient, immunocompetent, mild disease
  • Supportive care: hydration, antipyretics, analgesics, bronchodilators for wheeze; no antivirals. 1
• Suspected/confirmed pneumonia or hypoxemia
  • Oxygen therapy titrated to target SpO2; escalate from nasal cannula to HFNO/NIV/IMV as needed; consider ECMO for refractory hypoxemia. These supportive strategies reduce mortality in viral pneumonias and are guideline‑endorsed, though derived from COVID‑19 supportive care frameworks. 2
  • Avoid routine antibiotics; start empirically only if bacterial pneumonia cannot be ruled out, then de‑escalate per cultures. Overuse increases harm. 2
  • Corticosteroids are not indicated for routine OC43; consider only for established indications (e.g., COPD/asthma exacerbation) or ARDS per ICU care; weigh risks in viral infection. 2
• Immunocompromised or high‑risk hosts (e.g., HSCT, solid organ transplant, high‑dose steroids, advanced comorbidities)
  • Admit early for close monitoring; strict infection control and supportive respiratory care as above. 2, 9
  • Antivirals: No high‑quality evidence or guideline supports any specific antiviral for OC43. Case reports (e.g., nirmatrelvir/ritonavir) are hypothesis‑generating only and should not guide routine care or expectation of benefit on mortality/QoL. If considered as salvage in exceptional cases, do so within multidisciplinary/IRB pathways and drug–drug interaction checks. 9, 10
• Rehabilitation/QoL
  • Early mobilization, pulmonary hygiene, and prompt weaning of oxygen reduce deconditioning and improve QoL; arrange follow‑up for persistent cough or post‑viral reactive airways. [General; consistent with supportive care principles 2]

Infection prevention and control

• Standard respiratory hygiene: mask when coughing/sneezing, hand hygiene, isolation while symptomatic; home isolation guidance mirrors other respiratory viruses. These measures reduce transmission and downstream morbidity in vulnerable contacts. 2

Decision algorithm (concise)

• URTI symptoms without risk factors, no hypoxemia: multiplex NAAT if result will change management or cohorting; otherwise supportive outpatient care. No antivirals. 1
• Suspected pneumonia or high‑risk patient: multiplex NAAT + chest imaging; monitor vitals and oxygenation. Start oxygen if SpO2 < 92–94%; avoid routine antibiotics unless bacterial coinfection suspected; escalate respiratory support per response. 2
• ICU triggers: escalating oxygen needs, persistent hypoxemia, work of breathing, shock—apply HFNO/NIV/IMV, consider ECMO for refractory hypoxemia. 2
• Immunocompromised with LRTI: admit, apply above supportive strategy; no guideline‑endorsed antiviral—use investigative therapy only within governance frameworks. 9

Nuances and divergences in evidence

• Strongest applicable guidance emphasizes supportive respiratory care (oxygen escalation, ICU strategies) and antibiotic stewardship; these principles are extrapolated from high‑quality COVID‑19 supportive guidelines and are appropriate for non‑SARS seasonal coronaviruses in absence of specific antivirals. 2
• Seasonal coronavirus guidance (IDSA/ASM) highlights NAAT diagnosis and largely benign course; severe outcomes are mainly in high‑risk hosts. No recommended antiviral exists. 1, 9
• Contradictory signals: isolated case report suggests possible nirmatrelvir/ritonavir benefit in a post‑HSCT OC43 pneumonia; this is uncontrolled and should not alter practice focused on mortality/QoL. 10

Common pitfalls and how to avoid them

• Pitfall: Treating every viral pneumonia with antibiotics. Avoid unless bacterial coinfection suspected; then de‑escalate promptly. 2
• Pitfall: Assuming CT pattern equals COVID‑19. Always confirm etiology with multiplex NAAT. 7, 1
• Pitfall: Off‑label antivirals without evidence. Prioritize supportive care; reserve experimental therapy for trials/compassionate frameworks. 9, 10
• Pitfall: Delayed oxygen escalation. Early, protocolized oxygen titration reduces morbidity and prevents crash intubations. 2